The first large study of the safety and effectiveness of a coronavirus vaccine in the United States began on Monday morning, according to the National Institutes of Health and the biotech company Moderna, which collaborated to develop the vaccine.
A volunteer in Savannah, Ga., received the first shot at 6:45 a.m., Dr. Anthony S. Fauci, the director of the National Institute of Allergy and Infectious Diseases, said at a news briefing.
The study, a Phase 3 clinical trial, will enroll 30,000 healthy people at about 89 sites around the country this summer. Half will receive two shots of the vaccine, 28 days apart, and half will receive two shots of a saltwater placebo. Neither the volunteers nor the medical staff giving the injections will know who will get the real vaccine.
Researchers will then monitor the subjects, looking for side effects. And their main goal will be to see if significantly fewer vaccinated people contract Covid-19, to determine whether the vaccine can prevent the illness. The study will also try to find out if the vaccine can avert severe cases of Covid and death; if it can block the infection entirely, based on lab tests; and if just one shot can prevent the illness.
A second company, Pfizer, announced late Monday afternoon that it had also begun a late-stage study of a coronavirus vaccine. Pfizer has been working with a German company, BioNTech. Their study will also include 30,000 people, from 39 states in the United States, and from Brazil, Argentina and Germany.
The first subjects received injections at the University of Rochester on Monday.
The government announced last week that it had reached a $1.95 billion deal to buy 100 million doses of Pfizer’s vaccine by the year’s end, but only if the trial proves it safe and effective.
Dr. Fauci estimated that the full enrollment of 30,000 people in the Moderna trial would be completed by the end of the summer, and that results might be available by November. Findings might emerge even earlier, he said, but added that he doubted it. He said that the high rates of transmission in some parts of the country, though unfortunate, would help speed up the process of determining whether the vaccine works.
- Don’t play ball: Canceled Major League games are the latest sign of how the virus has upended summer.
- Republicans seek to slash expiring jobless payments by two-thirds as part of $1 trillion recovery bill.
- Trump, reverting to form, says ‘governors should be opening up states that they’re not reopening.’
Dr. Mark Mulligan, the director of the NYU Langone Vaccine Center in New York, which will begin giving injections of the Pfizer vaccine on Tuesday, said he thought that full enrollment would take two months, and that it would take four to six months to determine whether the vaccine worked.
Over all, a total of 150 to 160 coronavirus infections in the study will be enough to determine whether the Moderna vaccine is acceptably effective — that is, if it protects 60 percent of those who receive it, Dr. Fauci said.
Ideally, he would like the figure to be higher, but he said 60 percent “would be a major, huge step at controlling this outbreak; we’ll take that amount.”
Dr. Francis Collins, the director of the National Institutes of Health, said the U.S. government was reaching out to groups hit hardest by Covid — older people, those with chronic diseases, Blacks, Latinx and Native Americans — to encourage them to participate in the study. He said that the pandemic had put health disparities into “sharp relief” and that extra efforts were needed to gain the trust of people in those groups who might be reluctant to sign up for a medical experiment.
Earlier tests of Moderna’s vaccine showed that it stimulated a strong immune response, with minor and transient side effects like sore arms, fatigue, achiness and fever. But exactly what type of immune response is needed to prevent the illness is not known, so Phase 3 studies are essential to determine whether a vaccine really works.
The Coronavirus Outbreak ›
Frequently Asked Questions
Updated July 27, 2020
-
Should I refinance my mortgage?
- It could be a good idea, because mortgage rates have never been lower. Refinancing requests have pushed mortgage applications to some of the highest levels since 2008, so be prepared to get in line. But defaults are also up, so if you’re thinking about buying a home, be aware that some lenders have tightened their standards.
-
What is school going to look like in September?
- It is unlikely that many schools will return to a normal schedule this fall, requiring the grind of online learning, makeshift child care and stunted workdays to continue. California’s two largest public school districts — Los Angeles and San Diego — said on July 13, that instruction will be remote-only in the fall, citing concerns that surging coronavirus infections in their areas pose too dire a risk for students and teachers. Together, the two districts enroll some 825,000 students. They are the largest in the country so far to abandon plans for even a partial physical return to classrooms when they reopen in August. For other districts, the solution won’t be an all-or-nothing approach. Many systems, including the nation’s largest, New York City, are devising hybrid plans that involve spending some days in classrooms and other days online. There’s no national policy on this yet, so check with your municipal school system regularly to see what is happening in your community.
-
Is the coronavirus airborne?
- The coronavirus can stay aloft for hours in tiny droplets in stagnant air, infecting people as they inhale, mounting scientific evidence suggests. This risk is highest in crowded indoor spaces with poor ventilation, and may help explain super-spreading events reported in meatpacking plants, churches and restaurants. It’s unclear how often the virus is spread via these tiny droplets, or aerosols, compared with larger droplets that are expelled when a sick person coughs or sneezes, or transmitted through contact with contaminated surfaces, said Linsey Marr, an aerosol expert at Virginia Tech. Aerosols are released even when a person without symptoms exhales, talks or sings, according to Dr. Marr and more than 200 other experts, who have outlined the evidence in an open letter to the World Health Organization.
-
What are the symptoms of coronavirus?
- Common symptoms include fever, a dry cough, fatigue and difficulty breathing or shortness of breath. Some of these symptoms overlap with those of the flu, making detection difficult, but runny noses and stuffy sinuses are less common. The C.D.C. has also added chills, muscle pain, sore throat, headache and a new loss of the sense of taste or smell as symptoms to look out for. Most people fall ill five to seven days after exposure, but symptoms may appear in as few as two days or as many as 14 days.
-
Does asymptomatic transmission of Covid-19 happen?
- So far, the evidence seems to show it does. A widely cited paper published in April suggests that people are most infectious about two days before the onset of coronavirus symptoms and estimated that 44 percent of new infections were a result of transmission from people who were not yet showing symptoms. Recently, a top expert at the World Health Organization stated that transmission of the coronavirus by people who did not have symptoms was “very rare,” but she later walked back that statement.
In a statement, Dr. Collins said, “Having a safe and effective vaccine distributed by the end of 2020 is a stretch goal, but it’s the right goal for the American people.” He said that despite the unprecedented speed in bringing this experimental vaccine to human testing, “the most stringent safety measures” were being maintained.
Moderna said in a statement that it would be able to deliver about 500 million doses a year, and possibly up to a billion doses per year, starting in 2021. The Massachusetts-based company, which has received nearly $1 billion from the federal government to develop a coronavirus vaccine, has said it will not sell the vaccine at cost, but for profit.
Moderna has not said what it will charge. “We will price it responsibly during the pandemic, to make sure it is broadly accessible,” a spokesman, Ray Jordan, said in an email. The company may change the price later, when the virus becomes endemic, “but that is not something we have settled at this time,” Mr. Jordan said.
Moderna shares were up more than 9 percent on Monday.
Pfizer has also said it would sell its product at a profit; the contract with the government works out to about $20 a shot, and people will need two.
Both the Moderna and Pfizer/BioNTech vaccines use a synthetic version of genetic material from part of the coronavirus, encased in tiny particles made of fat that help it get into human cells. The genetic material, called messenger RNA or mRNA, then prompts the cells to churn out a tiny piece of the virus, which the immune system sees as foreign and learns to recognize. If the person is later exposed to the real virus, the immune system will attack it.
Messenger RNA has not yet produced any approved vaccines, but other companies have also invested in the approach, because of its potential to produce vaccine quickly. CureVac and Sanofi are also working on mRNA vaccines.
At the news briefing, Dr. Collins said that three more Phase 3 trials would be starting soon, each needing 30,000 patients. Those trials will involve vaccines made by Novavax, Johnson & Johnson and a collaboration of the University of Oxford and AstraZeneca. All three companies are part of the Trump administration’s Operation Warp Speed. Pfizer is not.
Adults interested in participating in the trials can visit coronaviruspreventionnetwork.org.
"and" - Google News
July 28, 2020 at 01:33AM
https://ift.tt/3f4kYZb
Moderna and Pfizer Begin Late-Stage Coronavirus Vaccine Trials - The New York Times
"and" - Google News
https://ift.tt/35sHtDV
https://ift.tt/2ycZSIP
And
Bagikan Berita Ini
0 Response to "Moderna and Pfizer Begin Late-Stage Coronavirus Vaccine Trials - The New York Times"
Post a Comment